Rudra Shares and Stock Brokers Ltd Broker Research reports

markets, Unlike in case of Maggi(from Nestle) couple of years back, which was contaminated with lead content coming from chemicals used in PVC pipes. Shift from toxic lead stabilisers to non-toxic stabilisers (Organotin stabilizers are the only alternative to lead-based...

Food testing business is seeing significant traction due to rising awareness about food safety, recent enforcement and activism by FASSI. There is also more increase in third party testing rather than in-house testing which will further be more beneficial for company. Hence the company has decided to set-up 9 more food testing labs across the country. Out of this labs at Bhimavaram, Kochi, Nellore, Pune and Visakhapatnam obtained required accreditations & commenced commercial operations. Accreditations for Ahmadabad, Bangaluru, Kolkata & Indore are under progress and commercial operations are expected to commence in third quarter which will further add to revenues and would be a major revenue driver for company in coming years.

VLL has also not leveraged itself and the debt on books is mainly taken to fund the expansion of food testing labs. With the expected strong growth in business fundamentals coupled with operating leverage over next few years profitability is expected to improve significantly. Therefore we recommend to BUY.

Clinical research and testing - Major Revenue Contributor - Provide stability Company has presence in pre-clinical testing having an strong analytical skills and provides these services to pharma, bio-tech, animal health, Bio-similar clients and medical device companies. Analytical division contribute around 45% of revenues which provides better stability to the overall business. In clinical research and testing India is rapidly gaining market share over China due to better quality and technology protection laws. Also the innovators are now outsourcing these operations to low cost countries due to better cost economics. Due to these factors industry as a whole is expected to grow at a good pace which would be...

Pidilite, a very good management company and is leading the market, is the promoter of Vinyl chemicals and of 50 % of the promoter stake, Pidilite is direct holding about 41 % stake in the company. Few years back, Vinyl had sold their plant at Mahad to Pidilite Industries as the entire production from this plant was getting sold to Pidilite Industries, (Pidilite being the big consumer of VAM) keeping VINYL as a trading company. Moreover, company's 90 % of the...

The need for security has grown exponentially, especially with pan-India customers needing security coverage for their physical assets. There exists a massive scope for frontline security services, which is being drive by the following :Strict enforcement of regulations such as minimum wages, Provident Fund norms, gratuity, insurance, among others. Increase in private infrastructure such as office complexes, industries and malls, among...

Generic pharmaceuticals business has been trending well for Abbott Labs for some time now. It has a broad line of branded generic pharmaceuticals manufactured worldwide, and marketed and sold outside the U.S. The major products sold through this segment include Creon, Brufen, Biaxin, Influvac and Duphaston, among others. Looking forward, company expects double-digit...

Demerger of the Human API Business into Solara Active Pharma Sciences Limited which will
also house the Commodity API Business of Strides Shasun Limited, will help achieve critical
scale & size and emerge as one of the largest API companies from India. This decision, to part
with the business from Sequent was taken considering the dynamic regulatory landscape in
API industry along with the growing opportunities for a pure-play API player from India. The
demerger awaits the final nod from the National Company Law Tribunal, Mumbai, and will
be value accretive for its shareholder.

Company entered into Distribution Services Agreement with Dr. Reddy's Laboratories to distribute Saxagliptin and with Sun Pharma to distribute Dapagliflozin and Ticagrelor under different brand names. During the year, these partnerships have enabled company to...

Robust product pipeline of promising niche products to fuel long term future growth, Strong Product Portfolio with significant brand market share in respective therapeutic segment, PANACEA is amongst the top 50 innovators in India with strong foundation of over two decades. Eyeing on Recent updates & highlights Amongst 6 WHO pre-qualified Suppliers of pentavalent vaccine US ANDAs - 3 approved; 3 pending for approval; 23 under development...

Company has a very well articulated plan for transition into the next phase of growth. There are a number of initiatives undergoing which will support the growth endeavors of the company. Company report a continued growth momentum supported by robust volume growth and better product mix. Increasing contribution from domestic business and significant improvement in export...